Mendel Lectures, Steve Jackson

• 7. dubna 2016
• Refektář Augustiniánského opatství, Mendlovo muzeum, Mendlovo náměstí 1a, Brno

---

Mendel Lectures 2015 / 2016
7 April 2016, 5 p.m.
Steve Jackson
Gurdon Institute, University of Cambridge, Cambridge, UK
Title: „Harnessing Genetic Principals to Treat Human Disease“

Stephen Philip Jackson, FRS, FMedSci, (born 17 July 1962 in Nottingham, England) is the Frederick James Quick Professor of Biology and a Fellow of St. John's College, Cambridge. He is a Senior Group Leader and Head of Cancer Research UK Laboratories at the Gurdon Institute, and an Associate Faculty member at the Wellcome Trust Sanger Institute. He is also part-time Chief Scientific Officer for MISSION Therapeutics Ltd.
Professor Jackson was educated at the University of Leeds, graduating with a Bachelor of Science degree in Biochemistry in 1983. He then carried out his PhD research working with Jean Beggs on yeast RNA splicing at Imperial College London and Edinburgh University, earning his PhD in 1987.

Following his PhD, Jackson carried out postdoctoral research with Robert Tjian at the University of California, Berkeley, where he developed an interest in the regulation of transcription. He returned to the UK in 1991 as a Junior Group Leader at the then Wellcome-CRC Institute, now the Gurdon Institute.

In 1997 Jackson founded KuDOS Pharmaceuticals with the aim of translating knowledge of DNA damage response pathways into new treatments for cancer. KuDOS developed into a fully integrated drug-discovery and drug-development company and was acquired by AstraZeneca in 2005.

In 2011 Jackson founded MISSION Therapeutics a firm to develop drugs to improve the management of life-threatening diseases, particularly cancer.

Jackson has received various prizes, including the Biochemical Society GlaxoSmithKline Award (2008), the BBSRC Innovator of the Year Award (2009) and the Royal Society Buchanan Medal (2011), the latter in recognition of his "outstanding contributions to understanding DNA repair and DNA damage response signalling pathways". He was elected a member of the European Molecular Biology Organization (EMBO) in 1997, a Fellow of the Academy of Medical Sciences in 2001 and a Fellow of the Royal Society in 2008.